For a description of binding specificities for IGF-1R, IR, and/or hybrid receptors [87] and comprehensive review of the dozen or more IGF-1R-targeted single-agent antibodies or small molecules now in preclinical development or early phase clinical trials, one may refer to a number of excellent reviews highlighting their possible therapeutic value for cancer in general [2,3,7,20,88-90], and sarcoma [6,33,91] or carcinoma [5,59,92] in particular. This evidence concerns the gene INSR and sarcoma.